Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Oral QPX7831 in Healthy Adult Subjects
Conditions
Interventions
QPX7831
placebo comparator
Locations
2
United States
Altasciences
Cypress, California, United States
CMAX
Adelaide, South Australia, Australia
Start Date
April 13, 2021
Primary Completion Date
August 30, 2022
Completion Date
August 30, 2022
Last Updated
October 10, 2022
NCT04263792
NCT06135350
NCT06322277
NCT06319235
NCT05824988
NCT05914467
Lead Sponsor
Qpex Biopharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions